相关临床试验
358
44 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
21
5.9%
已完成
184
51.4%
Enrolling By Invitation
4
1.1%
尚未招募
19
5.3%
招募中
67
18.7%
暂停
4
1.1%
终止
10
2.8%
Unknown
35
9.8%
撤回
14
3.9%
暂无批准数据
- Researchers used AlphaFold 3 AI to identify OPG153, a previously unconsidered viral surface protein, as a promising target for monkeypox virus vaccines and antibody therapies. - The breakthrough emerged from reverse vaccinology, analyzing antibodies from mpox survivors to predict which of 35 viral surface proteins they bind to most effectively. - Mouse studies demonstrated that injection with the AI-recommended viral protein produced neutralizing antibodies against MPXV, suggesting potential for simpler and cheaper vaccine development. - The discovery could accelerate development of treatments for both mpox and smallpox, with the team now working to optimize vaccine antigens and antibodies for human testing.
- CastleVax has dosed the first participant in a Phase 2 clinical study of CVAX-01, an intranasal COVID-19 vaccine candidate designed to elicit mucosal immunity and prevent breakthrough infections. - The study will enroll approximately 200 adults to evaluate safety, tolerability, and immunogenicity compared to FDA-approved mRNA vaccines, with participants followed for 6 months. - Preclinical studies demonstrated that the Newcastle Disease Virus-vectored vaccine protected animals from SARS-CoV-2 infection and blocked virus transmission through mucosal immune responses. - The vaccine utilizes HexaPro technology and has already received full regulatory approval in Thailand and Emergency Use Authorization in Mexico for intramuscular administration.
- Researchers from The University of Texas at Austin and Sanofi have developed RiboNN, an artificial intelligence model that predicts how efficiently specific mRNA sequences will produce proteins in different cell types. - The model demonstrated twice the accuracy of previous approaches when tested across more than 140 human and mouse cell types, potentially reducing trial-and-error experimentation in mRNA therapeutic development. - RiboNN could enable targeted therapies for specific organs like the liver or lung by optimizing mRNA sequences for enhanced protein production in particular cell types. - The tool has been made publicly available to accelerate research in cancer, infectious diseases, and genetic disorders through improved mRNA vaccine and drug design.
- New research reveals that while pancreatic cancer diagnoses are increasing among young adults, mortality rates remain stable, suggesting improved detection rather than rising disease prevalence. - The study found that pancreatic endocrine tumors, which are typically less aggressive, account for most of the increase in diagnoses, while rates of more lethal pancreatic adenocarcinoma have remained consistent. - Researchers warn about potential overdiagnosis leading to unnecessary surgeries, as pancreatic operations carry significant risks of complications and mortality.
- University of Utah researchers demonstrated safe and effective ultrasound-activated drug delivery to specific brain regions in non-human primates using multilayered nanoparticles. - The three-layer nanoparticle system successfully released propofol anesthetic in targeted visual brain areas, causing predictable behavioral changes without systemic side effects. - The technology achieved a 30-minute circulation window and showed potential for treating neurological disorders, cancer, and pain with reduced drug exposure to healthy tissues. - Parallel research from UT Austin developed hydrogen-bonded organic frameworks that can be programmed for ultrasound-triggered drug release using mechanochemical bond scission.
